Physician profile
Gregory L Spangler
NPI 1780606046
$31,298.44
in general payments reported to CMS, 2019-2025
56 companies · $6,806 in 2025
The $6,806 reported for 2025 was more than what 98% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,445 · 2020: $2,069 · 2021: $3,196 · 2022: $4,569 · 2023: $5,512 · 2024: $5,701 · 2025: $6,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Education: $25.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,993.12 |
| Education | $25.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,346.01 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $3,832.89 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $3,529.37 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,808.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $1,599.68 | 2019-2020 | |
| Pfizer INC. | $1,586.50 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,499.59 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $1,136.57 | 2022-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $919.60 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $907.67 | 2019-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $754.11 | 2024-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $741.25 | 2021-2025 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $699.12 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Axsome Therapeutics, INC. | $675.38 | 2023-2025 | Auvelity, Symbravo |
| Esperion Therapeutics, INC. | $634.79 | 2021-2025 | Nexletol |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $565.54 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $475.12 | 2023-2025 | Ingrezza, Ongentys |
| Amgen INC. | $467.83 | 2019-2025 | Evenity, Prolia, Otezla |
| Phathom Pharmaceuticals, INC. | $442.33 | 2023-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $362.78 | 2020-2025 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $351.10 | 2022-2024 | Quviviq |
| Amarin Pharma, INC. | $346.96 | 2019-2020 | |
| Antares Pharma, INC. | $330.78 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Biohaven Pharmaceuticals, INC. | $298.03 | 2021 | |
| Corium, LLC | $274.27 | 2022-2024 | Azstarys |
| Exact Sciences Corporation | $229.24 | 2023-2024 | Cologuard Collection Kit |
| Lundbeck LLC | $213.04 | 2023-2025 | Rexulti |
| Corcept Therapeutics | $192.62 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $187.58 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.05 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $177.30 | 2019-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $173.54 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $169.79 | 2019-2020 | |
| Edwards Lifesciences Corporation | $154.62 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Inspire Medical Systems, INC. | $138.73 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company Ltd. | $128.52 | 2022 | |
| Dexcom, INC. | $113.51 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $105.13 | 2024-2025 | Freestyle Libre 3 |
| Biogen, INC. | $104.80 | 2021 | |
| Ironshore Pharmaceuticals INC. | $76.14 | 2022-2023 | Jornay Pm |
| Mylan Specialty L.P. | $59.77 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $56.36 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $29.70 | 2025 | Spravato |
| Tris Pharma INC | $29.07 | 2023-2024 | Dyanavel Xr |
| Sanofi Pasteur INC. | $24.64 | 2023 | |
| Ardelyx, INC. | $23.15 | 2025 | Ibsrela |
| Scilex Pharmaceuticals INC. | $19.43 | 2024 | |
| Amneal Pharmaceuticals LLC | $18.51 | 2024 | Unithroid |
| Viatris Specialty LLC | $17.64 | 2025 | Yupelri |
| Cranial Technologies, INC | $16.56 | 2023 | Doc Band |
| Dynavax Technologies Corporation | $14.60 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.55 | 2024 | Zoryve |
| Melinta Therapeutics, LLC | $12.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.39 | 2022 | |
| Shire North American Group INC | $11.11 | 2019 | |
| Merck Sharp & Dohme LLC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Spangler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.